There are now multiple forms of injectable PrEP medications. Lenacapavir, which is Gilead's injectable drug, differs from ...
GlobalData on MSN4d
Gilead’s lenacapavir: HIV prospects strongest in long-acting combos with Merck’s islatravirGilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, ...
Louisville Public Media on MSN3d
This preventive drug could be a 'game changer' in ending the HIV epidemicIn newly released data, lenacapavir, given via a twice-yearly injection, has shown remarkable effectiveness at eliminating ...
The process for translating clinical trial results into action for young women in Africa has been left to our imaginations, ...
Potential to revolutionize HIV prevention. Ethel Weld, an Assistant Professor of Medicine at Johns Hopkins University School ...
ThePrint on MSN2d
Why Indian patients groups are opposing patent requests for blockbuster HIV drug lenacapavirGranting patents to US firm Gilead Sciences for lenacapavir could hinder global efforts to end AIDS & restrict access to ...
Gilead researchers say lenacapavir “has the potential to be one of the most impactful interventions” in the battle against ...
Twice-yearly lenacapavir was found to be superior to daily emtricitabine 200mg and tenofovir disoproxil fumarate 300mg.
A drug currently used to treat HIV has also been found to dramatically reduce the risk of infection, significantly more than the primary option available for pre-exposure prophylaxis or PrEP.
It could be a real breakthrough for people at risk for HIV infection: A shot given every six months that reduces their risk ...
On September 19, 2024, the Indian Patent Office will hear objections filed by Sankalp Rehabilitation Trust against Gilead's ...
Gilead Sciences' Phase 3 trial results show twice-yearly HIV-1 capsid inhibitor lenacapavir reduced HIV infections by 96%, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback